Literature DB >> 8077715

Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease.

A Norrby-Teglund1, K Pauksens, S E Holm, M Norgren.   

Abstract

The proliferative response of lymphocytes induced by a new streptococcal mitogenic factor (MF) and the streptococcal pyrogenic exotoxins (Spe) A and B was determined in sera from 6 healthy persons. Responses were compared to those obtained from reference serum that lacked mitogen-specific ELISA antibodies. The sera showed individual variations in the levels of MF- and Spe-specific antibodies, as determined by ELISA. The experiments showed that most human sera, which contained mitogen-specific antibodies, could neutralize the mitogenicity of the proteins. However, there were sera that contained mitogen-specific antibodies but that did not inhibit the toxin-induced proliferation. Thus, the ELISA antibody titer did not always equal the neutralizing capacity. Sera from 27 patients with group A streptococcal bacteremia had significantly lower neutralizing ability against MF and SpeB than did sera from 25 uncomplicated tonsillitis cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077715     DOI: 10.1093/infdis/170.3.585

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.

Authors:  M Roggiani; J A Stoehr; S B Olmsted; Y V Matsuka; S Pillai; D H Ohlendorf; P M Schlievert
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo.

Authors:  S U Kazmi; R Kansal; R K Aziz; M Hooshdaran; A Norrby-Teglund; D E Low; A B Halim; M Kotb
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study.

Authors:  Kim Ekelund; Jessica Darenberg; Anna Norrby-Teglund; Steen Hoffmann; Didi Bang; Peter Skinhøj; Helle Bossen Konradsen
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.

Authors:  Per Akesson; Linnea Moritz; Mikael Truedsson; Bertil Christensson; Ulrich von Pawel-Rammingen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Streptococcal DNase B is immunologically identical to superantigen SpeF but involves separate domains.

Authors:  A Eriksson; B Eriksson; S E Holm; M Norgren
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

7.  Relative avidities of human immunoglobulin G antibodies for streptococcal pyrogenic exotoxins A and B.

Authors:  E M Mascini; M Jansze; J Verhoef; H van Dijk
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 8.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

9.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.

Authors:  Samir S Shah; Matthew Hall; Raj Srivastava; Anupama Subramony; James E Levin
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.